Category: Thoratec Corp.
Results from Thoratec's Roadmap study of its HeartMate II implantable heart pump in less-sick heart failure patients shows significant benefit over optimal medical therapy alone.
Higher-than-expected stroke rates reported in a pair of studies of HeartWare's implantable heart pump this week spook investors, pushing HTWR share prices down more than 8%.
The FDA approves an expansion of the clinical trial for Thoratec's next-generation implantable heart pump, the HeartMate III device.
Thoratec reports higher-than-forecast earnings for the 4th quarter and 2014, on an extra selling week and higher utilization rates for its implantable heart pumps, and says it will narrow its focus to the ventricular assist device market.
Thoratec (NSDQ:THOR) yesterday reported higher-than-forecast earnings for the 4th quarter and 2014, crediting an extra selling week and better utilization rates for its implantable heart pumps.
Thoratec completes enrollment in a European clinical trial for its HeartMate III left ventricular assist device.
Thoratec's 3rd-quarter earnings plunge nearly 85% as sales decline more than 16%, raising fears that the left ventricular-assist device market is in a slump that could persist into 2015.
Thoratec (NSDQ:THOR) yesterday said its 3rd-quarter profits plunged some 85%, missing forecasts, and dimmed its outlook for the rest of the year.
Allergan CEO David Pyott steps down from the board at Edwards Lifesciences to devote more time to his chief executive duties.
, Boston Scientific
, Edwards Lifesciences
, LensAR Inc.
, LifeCell Corp.
, Polaris Industries
, Premier Inc.
, Sensory Medical
, STAAR Surgical Co.
, Thoratec Corp.
, Allergan Inc.